Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut
Oct 11 (Reuters) - Shares of Upstream Bio UPB.O opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shilpi Majumdar) ((ArasuKannagi.Basil@thomsonreuters.com;))
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs